What's new in IDIS:

 • New Drugs

 • Drug Name/Code Changes

 • FDA Approval Packages

 • FDA Pediatric Reviews

 • Advisory Committee Meetings

 • Black Box Warnings

 • Continuing Education Articles

 • Priority Clinical Practice Guidelines

 

 

IDIS Training Tools

 

Stay Connected:

 • IDIS on Facebook

 • Join Our Update Lists

 • CAMIPR

 • Monthly Update Information

 

 

Email: idis@uiowa.edu


Drug Information Resources

IDIS Logo   IDIS Monthly Update Information - June 2013

NEW DRUG TERM
AZD-2423
AZD-9668
BC-3781
EC90 VACCINE
EFINACONAZOLE
EPICATECHINS
GS-9667
GSK-1322322
HYPTIS VERTICILLATA
IODO-2-PYRIMIDINONE-2-DEOXY,5-
METUXIMAB,I 131-
MIRAVIRSEN
OLODATEROL
PENTADECANOIC ACID
PERFLUOROHEXANE
SCY-635
SERINE, D-
TC 99M HYNIC-TATE
TMX-101
TRIHEPTADECANOIC ACID
VTP-27999

CODE
95000354
44100114
8122958
10120644
8120528
88320005
24060057
8122957
92510297
10121057
10120309
14000725
12120103
95000609
94000144
8180130
40200453
78040278
10121056
95000610
24080111



DRUG NAME/CODE CHANGES

OLD TERM & CODE
BIBW-2992 10120942
DEBIO-025 8180077
FLAVOPIRIDOL 10120167

NEW TERM & CODE
AFATINIB 10120942
ALISPORIVIR 8180077
ALVOCIDIB 10120167


FDA APPROVAL PACKAGES

Article Numbers 698236-698238: Aripiprazole, Abilify, FDA Approval Package for NDA 21-436/S-029, 21-729/S-014, 21-713/S-021, and 21-866/S-016. FDA Approval Package 2011.

Article Numbers 698220-698235: Canagliflozin, Invokana Tablets, FDA Approval Package for NDA 204042. FDA Approval Package 2013.


FDA PEDIATRIC REVIEWS

Article Numbers 698216-698219: Argatroban, Acova, FDA Pediatric Review for NDA 20-883/S-014. FDA Pediatric Review 2008.

Article Numbers 698213-698215: Aripiprazole, Abilify, FDA Pediatric Review for NDA 21-436/S-027. FDA Pediatric Review 2009.

Article Numbers 698209-698212: Aripiprazole, Abilify, FDA Pediatric Review for NDA 21-436/S-021, 21-713/S-016, 21-729/S-008, and 21-866/S-008. FDA Pediatric Review 2008.


ADVISORY COMMITTEE MEETINGS

Article Numbers 698195-698201: Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee, April 18, 2013. FDA Advisory Committee 2013.

Article Numbers 698188-698194: Pulmonary-Allergy Drugs Advisory Committee Meeting, April 17, 2013. FDA Advisory Committee 2013.

Article Numbers 697623-697633: Oncologic Drugs Advisory Committee Meeting, May 2, 2013. FDA Advisory Committee 2013.

Article Numbers 697616-697622: Pulmonary-Allergy Drugs Advisory Committee Meeting, January 29, 2013. FDA Advisory Committee 2013.


BLACK BOX WARNING

Article Number 698187: Dabigatran Etexilate Mesylate: FDA Black Box Warning. 2013.


CONTINUING EDUCATION ARTICLES

Article Number 698506: Dager W E. Developing a Management Plan for Oral Anticoagulant Reversal (Ref Art 698503) (0.25 CEU) [IDIS Note: The 2.5 Hours of CE Credit is for All Articles in this Issue, Article Numbers 698503-698506]. Am J Health-Syst Pharm 2013, 70:S21-S31.

Article Number 698505: Kalus J S. Pharmacologic Interventions for Reversing the Effects of Oral Anticoagulants (Ref Art 698503) (0.25 CEU) [IDIS Note: The 2.5 Hours of CE Credit is for All Articles in this Issue, Article Numbers 698503-698506]. Am J Health-Syst Pharm 2013, 70:S12-S21.

Article Number 698504: Nutescu E A. Oral Anticoagulant Therapies: Balancing the Risks (Ref Art 698503) (0.25 CEU) [IDIS Note: The 2.5 Hours of CE Credit is for All Articles in this Issue, Article Numbers 698503-698506]. Am J Health-Syst Pharm 2013, 70:S3-S11.

Article Number 698503: Nutescu E A. New Approaches to Reversing Oral Anticoagulant Therapy: Introduction (Ref Art 698504-698506) (0.25 CEU) [IDIS Note: The 2.5 Hours of CE Credit is for All Articles in this Issue, Article Numbers 698503-698506]. Am J Health-Syst Pharm 2013, 70:S1-S2.

Article Number 698502: Anonymous. Pasireotide (Signifor) for Cushing's Disease (0.1 CEU) [IDIS Note: The 1.0 Hour of CE Credit is for All Articles in this Issue, Article Numbers 698501 and 698502]. Med Lett Drugs Ther 2013, 55:39-40.

Article Number 698501: Anonymous. Canagliflozin (Invokana) for Type 2 Diabetes (0.1 CEU) [IDIS Note: The 1.0 Hour of CE Credit is for All Articles in this Issue, Article Numbers 698501 and 698502]. Med Lett Drugs Ther 2013, 55:37-39.

Article Number 696907: Anonymous. Drugs for Psychotic Disorders (0.2 CEU) (Erratum) (Art 642137). Treat Guidel Med Lett 2013, 11:52.

Article Number 696906: Anonymous. Drugs for Allergic Disorders (0.2 CEU). Treat Guidel Med Lett 2013, 11:43-52.

Article Number 696804: Cada D J, Levien T L, Baker D E. Perampanel (0.15 CEU). Hosp Pharm 2013, 48:321-331.


PRIORITY CLINICAL PRACTICE GUIDELINES

Article Number 698384: Horwich A, Hugosson J, De Reijke T, Wiegel T, et al. Prostate Cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol 2013, 24:1141-1162.


College of Pharmacy